| ADMA Biologics is a biopharmaceutical and immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases. Co.'s marketed products consist of: Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen; and Bivigam, which is indicated for the treatment of primary humoral immunodeficiency. Co. is also developing a pipeline of plasma-derived therapeutics, including its key pipeline product candidate, RI-002, for the treatment of Primary Immune Deficiency Disease. We show 27 historical shares outstanding datapoints in our ADMA shares outstanding history coverage, used to compute ADMA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADMA market cap history over the course of time is important for investors
interested in comparing ADMA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADMA versus a peer is one thing; comparing
ADMA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADMA can fluctuate over the course of history.
With this page we aim to empower investors researching ADMA by allowing them to research the ADMA market cap history.